- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
AgraFlora received a cannabis research licence, giving it the ability to develop cannabis-infused beverages at its facility in Toronto.
AgraFlora Organics International (CSE:AGRA,OTCPK:AGFAF) has been awarded a cannabis research licence from Health Canada, giving the company the ability to develop cannabis-infused beverage formulations at its GMP bottling facility in Toronto, Ontario.
As quoted in the press release:
In anticipation of the Research Licence, AgraFlora began comprehensive retrofit initiatives at the Toronto Bottling Facility including the completion of a cannabis research laboratory (the “Research Laboratory”) within its current GMP-certified premises. The Research Laboratory consists of state-of-the-art equipment for weighing, handling and processing microdosages of CBD and THC compounds, including magnetic mixers, homogenizers and high-pressure liquid chromatograph (“HPLC”).
The Company plans to immediately commence cannabinoid-related research and development activities, including:
- Establishment of extraction protocols to isolate specific desirable compounds, including CBD, THC and THCV;
- Cannabinoid extract infusion analysis relating to formulation and pilot batching;
- Identification of process and physiochemical product attributes paired with analytically guided optimization;
- Development of optimized blend formulations for water solubility and shelf stability ratios/forms;
- High-pressure homogenization to produce superfine emulsions from cannabis oil; and,
- Centrifugal partition chromatography to develop compounds in a powdered format.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.